8 assets in RET Fusion Positive Cancer

Therapeutic assets addressing RET Fusion Positive Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Carboplatin RET Fusion Positive Cancer	Guangdong Provincial People's Hospital	P2	CCC (53)
Toripalimab RET Fusion Positive Cancer	Guangdong Provincial People's Hospital	P2	CCC (53)
Pralsetinib, Trans- RET Fusion Positive Cancer	Fudan University	P1/2	CCC (52)
HM06 RET Fusion Positive Cancer	Taiho Pharmaceutical Co., Ltd.	P1/2	CCC (48)
Lmv-12 RET Fusion Positive Cancer	Hunan Province Tumor Hospital	P1/2	CCC (48)
TAS0953 RET Fusion Positive Cancer	Taiho Pharmaceutical Co., Ltd.	P1/2	CCC (48)
aps03118 RET Fusion Positive Cancer	Applied Pharmaceutical Science, Inc.	P1	CC (43)
Leucogen RET Fusion Positive Cancer	Fudan University	N/A	D (30)